Constitutively active androgen receptor variants upregulate expression of mesenchymal markers in prostate cancer

Félicie Cottard1, Irène Asmane, Eva Erdmann

  • 1INSERM U1113, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France.

Plos One
|May 10, 2013
PubMed

Insights

Constitutively active androgen receptor (AR) variants promote prostate cancer progression by increasing N-cadherin and other mesenchymal markers. This finding offers new insights into castration-resistant prostate cancer (CRPC) therapeutic targets.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • The androgen receptor (AR) signaling pathway is a key therapeutic target for castration-resistant prostate cancer (CRPC).
  • Constitutively active AR variants, lacking the carboxy-terminal region, are implicated in CRPC and may drive tumor progression despite androgen depletion.
  • The precise mechanisms by which these AR variants promote cancer progression remain unclear.

Purpose of the Study:

  • To investigate the impact of constitutively active AR variants on the expression of tumor progression markers in prostate cancer.
  • To elucidate the role of these variants in the context of castration-resistant prostate cancer.

Main Methods:

  • Overexpression of wild-type AR and constitutively active AR variants in LNCaP and C4-2B prostate cancer cell lines.
  • Analysis of N-cadherin, Vimentin, SNAIL, and ZEB1 expression using qRT-PCR, Western blot, and immunofluorescence.

Main Results:

  • Constitutively active AR variants significantly increased N-cadherin expression in prostate cancer cells.
  • Upregulation of other mesenchymal markers, including VIMENTIN, SNAIL, and ZEB1, was observed in the presence of these AR variants.
  • Downregulation of E-cadherin was not observed, despite the increase in N-cadherin.

Conclusions:

  • Constitutively active AR variants play a significant role in regulating mesenchymal markers, suggesting a novel mechanism for prostate cancer progression.
  • These findings highlight potential new therapeutic strategies targeting AR variants in CRPC.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Master Transcription Regulators02:23

Master Transcription Regulators

Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...